Gilead Sciences (GILD) Data Shakes-Up Hep-C Space (VRTX) (IDIX) (ACHN)
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Up)Join SI Premium – FREE
Vertex Pharmaceuticals Incorpor (Nasdaq: VRTX) is moving up 7 percent in pre-open trading Friday following disappointing data from Gilead Sciences, Inc. (Nasdaq: GILD) on its Hep-C treatment, showing viral relapse in first month.
Elsewhere in the Hep-C space, Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) is down 11% and Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is not trading yet.
Elsewhere in the Hep-C space, Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) is down 11% and Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is not trading yet.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Rubrik (RBRK) Prices 23M Share IPO at $32/sh, Above Indicated $28-$31/sh Range - Reuters
- European stocks retreat on earnings gloom, weak US economic data
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
